Related Experiment Video

Updated: Jul 11, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Thalidomide in Kaposi sarcoma: promising or disappointing?

Emmanuel Laffitte

    Dermatology (Basel, Switzerland)
    |September 8, 2007
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
    09:53

    An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

    Published on: August 25, 2017

    Related Experiment Videos

    Last Updated: Jul 11, 2026

    Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
    10:44

    Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

    Published on: May 15, 2019

    An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
    09:53

    An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

    Published on: August 25, 2017

    Related Concept Videos

    Therapeutic Drug Monitoring: Affecting Factors01:29

    Therapeutic Drug Monitoring: Affecting Factors

    Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

    Articles linked to this work by shared authors, journal, and citation graph.

    Swiss S1 Guidelines for the Management of Hidradenitis Suppurativa.

    Dermatology (Basel, Switzerland)·2026

    [Acne and mycoses : between non-drug treatments and resistance].

    Revue medicale suisse·2025

    Updated Swiss Practice Recommendations for the Treatment of Acne.

    Praxis·2025

    Small Fiber Neuropathy in Long COVID: A Cohort Study with Multimodal Assessment and Follow-Up.

    European neurology·2025

    [Vitiligo and alopecia areata in children : the dermatologist's perspective].

    Revue medicale suisse·2025

    [Dermatology. New uses for JAK inhibitors in dermatology: a panacea, but at what price?]

    Revue medicale suisse·2024

    Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast.

    Dermatology (Basel, Switzerland)·2026

    Immunocryosurgery as Primary Treatment for Lentigo Maligna and as an Adjuvant Therapy for Lentigo Maligna Melanoma: A 21-Patient Case Series.

    Dermatology (Basel, Switzerland)·2026

    Atopic disease prevalence by nativity, citizenship, and years of residence in the United States.

    Dermatology (Basel, Switzerland)·2026

    Comparison of missed appointments between children with tinea capitis and those with other skin diseases: A case-control study.

    Dermatology (Basel, Switzerland)·2026

    Advances in current and emerging therapies for challenging cutaneous mucinoses with substantial morbidity and therapeutic complexity: A narrative review.

    Dermatology (Basel, Switzerland)·2026

    Eczematous component in psoriasis is possibly a negative prognostic factor for deucravacitinib treatment outcome.

    Dermatology (Basel, Switzerland)·2026

    Evaluating the Effects of Inpatient Only (IPO) Policy Changes on Anterior Cervical Discectomy and Fusion: Access and Outcomes Across Payer Groups.

    Global spine journal·2026

    Similarities and differences in the late-onset GM2 gangliosidoses: Tay-Sachs and Sandhoff diseases.

    Journal of neurology·2026

    A Silent Gap: Underrepresentation of Latin American Patients in Pivotal Genitourinary and Skin Cancer Trials.

    The oncologist·2026

    Extradigital glomangioma: a rare occurrence.

    Skin health and disease·2026

    He Was Always There.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Extrauterine Low-Grade Endometrial Stromal Sarcoma: A Case Report and Review of the Literature.

    Diagnostics (Basel, Switzerland)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us